Related Experiment Video
Updated: Jul 2, 2026
06:02
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Cutaneous reaction associated with weekly docetaxel administration.
Lita Chew1, Vivianne Shih Lee Chuen
1National Cancer Centre Singapore, National University of Singapore, 11 Hospital Drive, Singapore 169610. phmcst@nccs.com.sg
Summary
Docetaxel chemotherapy can cause significant skin reactions in patients with metastatic breast cancer. Early recognition and management are crucial for patient care and treatment adherence.
Area of Science:
- Oncology
- Dermatology
- Clinical Pharmacy
Background:
- Docetaxel remains a key chemotherapy agent for metastatic breast cancer.
- Weekly docetaxel (35 mg/m2) is associated with a 19% incidence of grade 3 cutaneous toxicity.
- Observed toxicities include erythrodysesthesia, erythema multiforme, nail changes, and flagellate erythema.
Observation:
- This report details four heavily pre-treated patients receiving docetaxel as second or third-line therapy.
- Cutaneous reactions manifested around cycle 5, developing 1-7 days after chemotherapy.
- Lesions resolved with desquamation, leading to temporary hyper- or hypo-pigmentation.
Findings:
- Management strategies involved supportive care (compresses, elevation), antibiotics, corticosteroids, and drug cessation.
- Reactions typically resolved within 2-3 weeks post-chemotherapy.
- The study highlights the varied presentations and resolution patterns of docetaxel-induced skin toxicity.
Implications:
- A systematic approach is necessary for managing docetaxel-induced cutaneous reactions.
- Oncology pharmacists are vital in patient assessment, management, documentation, and education.
- Effective management can improve patient adherence and outcomes in docetaxel therapy.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:27Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...